When did Axsome Therapeutics report Q4 2024 earnings?

Axsome Therapeutics (AXSM) reported Q4 2024 earnings on February 18, 2025 before market open.

What were Axsome Therapeutics's Q4 2024 revenue and EPS?

Axsome Therapeutics reported revenue of $118.8M and eps of $-0.96 for Q4 2024.

Did Axsome Therapeutics beat estimates in Q4 2024?

Revenue missed the consensus estimate of $119.5M by $740.4K. EPS beat the consensus estimate of $-1.00 by $0.04.

Where can I find Axsome Therapeutics's Q4 2024 SEC filings?

You can read the 10-K periodic report (0000950170-25-022457) directly on SEC EDGAR. The filing index links above go to sec.gov.

Axsome Therapeutics AXSM Q4 2024 Annual earnings

Reported February 18, 2025 · Before market open

Revenue$118.8MMiss by $740.4K

EPS-$0.96Beat by $0.04

Revenue estimate$119.5M

EPS estimate-$1.00

Next report

Aug 10, 2026 (In 1 week)

Revenue estimate$220.9M

EPS estimate-$0.89

Financials

Q4 2024

Income statement

See full

Revenue$118.8M+66.0%

Gross profit$108.3M+68.7%

Operating income-$72.6M+26.1%

Net income-$74.9M+24.1%

EPS (diluted)-$1.54+27.7%

Balance sheet

See full

Cash & equivalents$315.4M-18.3%

Total debt$193.0M+3.5%

Total equity$57.0M-70.1%

Total assets$568.5M-3.4%

Cash flow

See full

Operating cash flow-$26.2M+13.7%

CapEx$30.0K+329%

Free cash flow-$26.2M+13.6%

Valuation & ratios

Valuation

as of 12/31/24

See full

Market cap$4.1B+8.9%

Enterprise value$3.98B+11.5%

P/S10.6×-3.3×

Profitability

See full

Gross margin91.4%+1.0pp

Operating margin-72.7%-9.5pp

Net margin-74.5%-10.1pp

FCF margin-33.4%-9.2pp

Returns & leverage

See full

Return on equity-231.6%+193pp

Debt / equity3.4×+2.4×

Current ratio2.1×-1.5×

Segments

By product

See full

Royalty And Milestone Revenue$1.0M—

Royalty$500.0K—

Versus estimates

Revenue

Q1 2026$189.4MMiss by $1.5M Q4 2025$194.7MBeat by $1.3M Q3 2025$171.0MMiss by $20.3M Q2 2025$150.0MBeat by $10.0M Q1 2025$121.5MMiss by $19.0M

Q4 2024$118.8MMiss by $740.4K

Diluted EPS

Q1 2026-$1.26Miss by $0.41 Q4 2025-$0.71Miss by $0.01 Q3 2025-$0.94Miss by $0.12 Q2 2025-$0.92Beat by $0.08 Q1 2025-$0.80Beat by $0.46

Q4 2024-$0.96Beat by $0.04

Ask the moment Axsome Therapeutics reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Claude

Questions, answered.

When did Axsome Therapeutics report Q4 2024 earnings?: Axsome Therapeutics (AXSM) reported Q4 2024 earnings on February 18, 2025 before market open.
What were Axsome Therapeutics's Q4 2024 revenue and EPS?: Axsome Therapeutics reported revenue of $118.8M and eps of $-0.96 for Q4 2024.
Did Axsome Therapeutics beat estimates in Q4 2024?: Revenue missed the consensus estimate of $119.5M by $740.4K. EPS beat the consensus estimate of $-1.00 by $0.04.
Where can I find Axsome Therapeutics's Q4 2024 SEC filings?: You can read the 10-K periodic report (0000950170-25-022457) directly on SEC EDGAR. The filing index links above go to sec.gov.